Hema.to provides fully automated, AI-powered blood cancer detection suggestions based on flow cytometry data.
Hema.to has raised $3.7M in total funding. The most recent round was Seed. The last funding was announced in February 2025.
Hema.to's investors include HTGF (High-Tech Gruenderfonds), LUMO labs, Heal Capital, Bayern Kapital, Elaia.
Hema.to is headquartered in München, Germany.
Hema.to provides fully automated, AI-powered blood cancer detection suggestions based on flow cytometry data.
Hema.to is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hema.to — Funding & Investors." VCBacked, February 27, 2025, https://www.vcbacked.co/company/hemato. Accessed September 15, 2026.
VCBacked. (2025). Hema.to — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/hemato
{{cite web |title=Hema.to — Funding & Investors |url=https://www.vcbacked.co/company/hemato |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated